GenScript Teams with Singapore Researchers on Anti-Fibrosis Therapeutics

New Jersey-based GenScript Biotech has partnered with Singapore’s Experimental Drug Development Center (EDDC) to develop treatments for patients with idiopathic pulmonary fibrosis (IPF).

EDDC is a national research organization that works with public-sector and industry partners to translate Singapore’s biomedical and clinical science research and development into innovative products.

The center will combine its recombinant antibody discovery platform with GenScript’s gene synthesis technology to “accelerate the development of new medicines for difficult-to-treat diseases such as IPF,” said EDDC’s CEO Damian O’Connell.